Infectious disease
Cell culture and mouse studies identified llama-derived single-domain antibodies against RSV F protein that could help treat RSV. In a non-human primate cell-based assay of RSV-induced plaque formation, screening of recombinant llama-derived single-domain antibodies identified two antibodies that neutralized RSV F protein with IC50 values of 0.038 and 0.089 nM. In a mouse model of RSV infection, one of the antibodies decreased lung plaques, viral load and immune cell infiltration in the lung compared with non-specific antibodies and decreased viral load compared with palivizumab. Next steps include clinical testing of the llama-derived single-domain antibodies.
AstraZeneca plc and Abbvie Inc. market Synagis palivizumab, a humanized mAb against RSV F protein, to prevent and treat RSV...
BCIQ Company Profiles
BCIQ Target Profiles